Table 2. Results of base-case analysis on costs, survival event rates and QALYs expected from surviving influenza infections among hospitalized adults.
| Strategy | Cost (USD) | Survival ratea | QALYsb | ICERc (USD) |
| Empirical treatment alone | 1,247 | 104.6 | 1.6917 | - |
| PCR-guided treatment | 1,248 | 104.5 | 1.6907 | Dominated |
| IFA-guided treatment | 1,249 | 103.8 | 1.6731 | Dominated |
| Empirical treatment plus PCR | 1,253 | 104.5 | 1.6907 | Dominated |
a
: Survivals of influenza infection per 1,000 patients presented with suspected influenza.
b
: Quality-adjusted life-years (QALYs) expected from patients infected with influenza A viruses.
c
: ICER = increment cost per QALY gained.